Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
CANOMAD syndrome (Chronic Ataxic Neuropathy, Ophthalmoplegia, Monoclonal IgM protein, cold Agglutinins and Disialosyl antibodies) is a rare chronic immune-mediated demyelinating polyneuropathy.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for CANOMAD syndrome.
5 publications have been identified in PubMed for CANOMAD syndrome. Research spans Review / Meta-Analysis (80%) and Case Report / Case Series (20%).
Jaccard A (2025). [PMID: 41348001](https://pubmed.ncbi.nlm.nih.gov/41348001/). *Hematology Am Soc Hematol Educ Program*. [Review / Meta-Analysis]
Encarnación JA (2025). [PMID: 40676639](https://pubmed.ncbi.nlm.nih.gov/40676639/). *J Med Case Rep*. [Case Report / Case Series]
Sarosiek S (2024). [PMID: 39680359](https://pubmed.ncbi.nlm.nih.gov/39680359/). *Curr Hematol Malig Rep*. [Review / Meta-Analysis]
Pascual-Goñi E (2024). [PMID: 39088795](https://pubmed.ncbi.nlm.nih.gov/39088795/). *Neurology*. [Review / Meta-Analysis]
Traub R (2024). [PMID: 38816958](https://pubmed.ncbi.nlm.nih.gov/38816958/). *Muscle Nerve*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:03 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about CANOMAD syndrome